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Abstract !
Purpose  
Our objectives were to 1) determine the difference in Rhabdomyosarcoma (RMS) 
incidence and survival between different race/ethnicity groups, and 2) evaluate the 
difference in survival of RMS between children and adults of these race/ethnicity 
groups, using the Surveillance, Epidemiology, and End Results Program (SEER) 
database between 1973-2013. 
Patients and Methods 
We analyzed racial characteristic and incidence data from 4,280 patients diagnosed 
with RMS, between 1973-2013, that were reported to the SEER database. Survival and 
hazard analyses were conducted on 4,268 patients with known follow-up data, with end 
point being death from any cause. 
Results 
Over the 40-year study period overall RMS incidence rates have experienced a 
statistically significant decline (APC: -0.78, 95% CI: -1.28 – -0.28). Whites have 
experienced a significant decline in incidence rates (APC: -1.05, 95% CI: -1.60 – -0.50). 
Though not statistically significant, incidence rates in Blacks and Hispanics have 
trended upwards. While adjusted survival was not predicted by race, survival did 
significantly differ among racial/ethnic groups in children, with Hispanics and “Others” 
having the lowest 5- and 10-year survival rates (65% and 58% verses 58% and 56%,
! !! ! ! ! !v!
respectively). Black race/ethnicity was also shown to be a predictor for mortality for the 
time period 1990-2013. 
Conclusion 
Racial/ethnic minorities have worse RMS clinical presentation and incidence rates than 
Whites. While overall survival is not predicted by race, being an ethnic minority child 
diagnosed with RMS is predictive of survival. These disparities point towards a genetic 
component in RMS that has not yet been described. 
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Introduction !
While the annual incidence of Rhabdomyosarcoma (RMS) among those younger 
than 20 years is 4.6 cases per million people [1,2], RMS is one of the most common 
childhood and adolescent tumors, representing more than 50% of soft tissue sarcoma 
cases in this age group [2,3], and nearly 3.4% of cancers overall [4]. Approximately 350 
children and adolescents in the United States (US) are diagnosed with RMS per year, 
with half of these cases occurring in patients under 10 years of age [1,2]. RMS can 
occur in those older than 20, though it is exceedingly rare [3], accounting for only 3% of 
soft-tissue sarcomas and less than 1% of cancers overall in this age group [4]. 
 RMS is a rare, highly malignant soft tissue sarcoma that originates from the 
embryonal mesenchyme [5,6], which imitates normal striated muscle tissue [7]. 
Although RMS tumors are typically found within striated muscle, they can occur virtually 
anywhere in the body [6,7], excluding bone [8]. RMS is further classified as embryonal 
(approximately 70% of cases), alveolar (approximately 30% of cases), pleomorphic, 
spindle cell, mixed-type, and RMS not otherwise specified (NOS) histologic subtypes 
[1,5], which makes it difficult to classify patients into homogenous treatment groups [8]. 
Due to the rarity of RMS, little is known about the etiology and epidemiology of this 
disease [6]. 
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Collaborative pediatric trials from the Intergroup Rhabdomyosarcoma Study 
Group (IRSG) have revolutionized the therapeutic methods for this sarcoma [8-10]. 
Based on the conclusions of these studies multimodality treatment regimens, involving 
chemotherapy and/or radiation, are decided by tumor staging (based on tumor primary 
site, tumor size, and the presence or absence of regional lymph node involvement and 
of distant metastasis), grouping (defined by the amount of residual tumor after initial 
surgery), and the histologic subtype of the tumor [8-10]. Pediatric patients with 
nonmetastatic disease have received the most benefit from these studies, with cure 
rates up to approximately 70% [3,5,11] from 25% in 1970 [5,11]. Prognosis in adults 
with RMS is very poor, with overall survival rates of 20% to 40% [3,4] verses rates of 
60% to 80% for children [4], calling into question whether or not chemotherapy (which is 
a key feature in pediatric treatment) should be used at all in adults [3]. Unfortunately this 
question is not easily answered, as large multi-institutional studies focusing on adult 
RMS have not been conducted, and only small, single institution reports have been 
published [3]. 
There are gaps in the literature involving regarding disparities in survival by race 
or ethnicity for RMS, for both adults and children [3,4,11-17]. This is presumably due to 
either limitations in the data prior to expansion of certain cancer registry programs, or as 
a result of underrepresentation of certain populations in clinical trials for cancer [18].  
Our objectives were to 1) determine the difference in RMS incidence and survival 
between race/ethnicity groups, and 2) evaluate the difference in survival of RMS 
between children and adults within these race/ethnicity groups, using the Surveillance, 
Epidemiology, and End Results Program (SEER) database between 1973-2013.
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Methods 
Data Source and Study Population 
The November 2015 release of SEER program data [19] were analyzed to 
evaluate incidence and survival rates of RMS in the United States between 1973 and 
2013. The SEER Program collects information from population-based registries on 
demographics, histology, tumor site, tumor stage at diagnosis, first course of treatment, 
and vital status [19]. The SEER 18 Program is an expansion on two previous SEER 
programs. The first, SEER 9, covered the states of Connecticut, Iowa, New Mexico, 
Utah, and Hawaii; the metropolitan areas of Detroit, Atlanta, San Francisco-Oakland, 
and Seattle-Puget Sound, starting in 1973 [19]. The next program, SEER 13, added 
registries in 1992 in Los Angeles, San Jose-Monterey, Alaska Native Registry, and rural 
Georgia, allowing for analysis on Hispanic populations [19]. The latest program, SEER 
18, added Kentucky, Greater California, New Jersey, Louisiana, and Greater Georgia, 
which increased program coverage to 30% of the US Population [19].  
The study population for this analysis is all microscopically confirmed cases of 
RMS. International Classification of Disease for Oncology, Third Edition (ICD-O-3) 
morphology codes were analyzed to include the following RMS subtypes: 8900/3 (RMS, 
NOS), 8901/3 (pleomorphic); 8902/3 (mixed type); 8910/3 (embryonal); 8912/3 (spindle 
cell); and 8920/3 (aveolar). A total of 4,325 RMS patients were identified from the SEER 
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data using the IDC-O-3 morphology codes. A total of 45 patients were excluded from 
the analysis either because they had no microscopic confirmation of diagnosis or 
diagnosis was confirmed by autopsy/death certificate only. After exclusion, 4,280 
patients remained in the analysis. A total of 12 patients were further excluded due to 
unknown survival time, leaving 4,268 patients in these analyses. A total of 30 patients 
with localized/regional prostate SEER stage were recoded as regional stage. Patients 
were further classified by age and diagnostic era. Pediatric patients are defined as 
being 19 years or younger, and adults as 20 years or older. Diagnosis era was divided 
into two categories: diagnosis in the period 1973 to 1989, and diagnosis in the period 
1990 to 2013. This was done for two reasons: first, because results from two pediatric 
clinical trials conducted by the IRSG [9,10] were made available, which revolutionized 
how RMS is treated; and second because the addition of SEER 13 registries in 1992 
expanded coverage, allowing for analysis of Hispanics [19]. Although SEER does not 
directly collect information on Hispanic ethnicity, SEER does code Hispanic origin using 
the North American Association of Central Cancer Registries (NAACCR) Hispanic 
Identification Algorithm (NHIA), which uses surname and maiden name to determine 
Hispanic ethnicity [19]. Race was coded as White, Black, Hispanic, and Other for this 
analysis. After recoding for Hispanic ethnicity, 44 patients in the 1973 to 1989 diagnostic 
era were further recoded from Hispanic ethnicity to “Other” because data on Hispanic 
ethnicity in this era was not specifically collected until SEER 13 program expansion in 
1992. Due to the rarity of RMS, and small cell counts, all other ethnicities (eg. American 
Indian/AK Native, Asian/Pacific Islander, unknown, etc) were recoded as “Other”, in 
both treatment eras, for the purposes of this analysis.  
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International Classification of Disease for Oncology, Third Edition (ICD-O-3) 
topography codes was used to define tumor primary site and tumor prognostic site. 
Prognostic site was classified as favorable for tumors of the nonparameningeal head 
and neck, the genitourinary system (excluding the kidney, bladder, and prostate), and 
the biliary tract, and as unfavorable for all other sites. Tumor stage was classified using 
the SEER staging system. Localized stage refers to an invasive tumor that is completely 
confined to its organ of origin; regional stage refers to a tumor that has expanded 
beyond its organ of origin, into surrounding tissues, and/or has spread to the regional 
lymph nodes; distant stage refers to a tumor that has spread to distant organs and 
tissue in remote parts of the body, and/or to distant lymph nodes [19].  
This study was determined to be exempt from human research regulations by the 
University of South Florida Institutional Review Board (IRB). 
Statistical Analysis 
Statistical Analyses were performed using SAS version 9.4 (SAS Institute, Cary, 
NC). Frequency distributions, total and stratified by race, were calculated for categorical 
variables, and means and standard deviations were calculated for continuous variables. 
Associations between categorical variables were tested using Chi-Squared tests, with 
an association deemed statistically significant if !! p-value<0.05. The effects of 
demographic, pathologic, clinical, and treatment variables on survival were tested using 
the univariate log-rank method for categorical variables. Multivariate analyses to test 
significant prognostic factors (overall, by diagnostic era, by age, and by race) were 
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conducted using the Cox proportional hazards regression. Cox modeling was further 
performed to analyze racial survival rates, while adjusting for age category, sex, 
diagnostic era, geographic region, histology, SEER stage of disease, primary tumor site 
prognosis, and treatment. Kaplan-Meier survival estimates were used to construct racial 
survival curves that were stratified by age category. Log-rank method was employed to 
compare the survival curves. 
SEER*Stat software (v. 8.3.2) was utilized to analyze incidence rates, trends, 
and annual percentage change (APC). The SEER 9 population data was analyzed from 
1973 to 2013 for Whites, Blacks, and Overall (all races), while the SEER 13 population 
data was used to analyze the time period was 1992 to 2013 for Hispanics. All incidence 
data were age-adjusted using the 2000 US Standard population and calculated per 
100,000 person-years of follow-up. To determine the APC, the weighted least squares 
method was used. P-values<0.05 were deemed statistically significant. Incidence rates 
and APC were not analyzed for the race category Others due to limitations with the 
SEER*Stat program. 
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Results 
Patient Characteristics 
Of the 4,268 RMS patients included in this study, 2,427 (56.9%) were classified 
as children (≤19 years) and 1,841 (43.1%) as adults. The median age of the entire 
sample was 16 years (± 26.5 years, range: birth to 98 years). While Whites, Blacks, and 
Others shared a similar median age to that of the overall, Hispanics had a lower median 
age of 12 years (± 21.0 years). Males comprise majority of the sample, at 2,410 patients 
(56.5%) verses females with 1,858 patients (43.5%). Significantly more patients were 
diagnosed in the latter diagnostic period of 1990-2013 (3,371, 79.0%). More than half of 
the RMS patients were diagnosed in the Western region (52.7%); however among 
Blacks more than a third (37.2%) were diagnosed in the Southern region (Table 1).  
Overall, Embryonal was the most common RMS histologic type with 1,698 
(39.8%) patients, followed by RMS NOS (1,044, 24.5%), Alveolar (974, 22.8%), 
Pleomorphic (395, 9.3%), Spindle Cell (85, 2.0%), and Mixed-type (72, 1.7%). Among 
all races: Blacks were more likely to develop Embryonal RMS; Hispanics more likely to 
develop Alveolar; and Whites more likely to develop RMS NOS. Regional metastasis 
was found to be the most common SEER stage in the sample, with 1,271 patients 
(29.8%), followed closely by localized (1,264, 29.6%), and distant disease (1,234, 
28.9%). Although localized disease was the most frequent among Whites, compared to 
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all races Blacks were more likely to develop localized disease. Distant disease was 
found to be most common among each Blacks and Hispanics, with Hispanics being the 
most likely to develop either regional or distant disease when compared to all races 
(Table 1). 
The most frequent tumor site for the entire sample was the head and neck, 
excluding the orbit, with 1,073 patients (25.1%). Although the trunk was the most 
common tumor site for Whites (767, 29.5%), Whites were more likely than any other 
race to develop extremity tumors. Among Blacks, the most frequent tumor site was also 
the trunk (173, 27.6%), and they were most likely race to develop genitourinary tumors. 
Head and neck tumors were the most common tumor site among Hispanics (196, 
29.5%), and were more likely to develop in Hispanics compared to all other races. In 
this sample, majority of patients had an unfavorable primary tumor site (2,712, 63.5%).  
For treatment, most patients received both radiation and surgery (1,300, 30.5%). 
Hispanics and Others were more likely than Whites to receive no treatment or radiation 
only. Whites were more likely than Blacks or Hispanics to receive surgery only, or both 
radiation and surgery (Table 1). 
Incidence and Annual Percentage Change 
 Across the entire study period, Whites had similar incidence rates to the overall 
rate, Blacks had higher rates for majority of the study period, and Hispanics 
experienced inconsistent rates (Figure 1). The overall APC for 1973 to 2013 is a 
statistically significant decline of -0.78 (95% CI: -1.28 to -0.28). Whites also experienced 
a statistically significant decline from 1973 to 2013, with an APC of -1.05 (95% CI: -1.60 
to -0.50). Blacks had an increased 1973 to 2013 APC of 0.39 (95% CI: -0.74 to 1.53), 
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though this increase was not statistically significant. Hispanics also experienced an 
increased APC of 1.29 (95% CI: -1.33 to 3.97), from 1992-2013, that was not 
statistically significant. 
Survival Analysis 
Survival for all races significantly dropped in the first 5 years, and then began to 
level off (Figure 2). The log-rank p-value is 0.23, meaning that the survival curves do not 
significantly differ and race is not a predictor of survival after adjustment for all other 
variables in the model. Overall 5-year survival rate was 56%, the 15-year rate was 52%, 
and the 30-year rate was 49%. For Whites the 5-, 15-, and 30-year survival rates were 
57%, 53%, and 51%, respectively; for Blacks the rates were 53%, 49%, and 46%; for 
Hispanics the rates were 56%, 52%, and 49%; and for Others the rates were 54%, 49%, 
and 47%. 
RMS survival by age, for each race is illustrated in Figure 3. The log-rank p-value 
for the survival curves is <.0001, meaning there is a significant difference in survival 
between children and adults. Child race categories Other and Hispanic had a 
statistically significant lower survival rate than Whites and Blacks (p-value: 0.03). The 5-
, 15-, and 30-year survival rates were: for children overall 65%, 62%, and 59%, 
respectively; for White children 66%, 63%, and 61%, respectively; for Black children 
62% represents all three survival rates; for Hispanic children 65%, 58%, and a 39% 22-
year survival rate; for Other children 58%, 56%, and 56%, respectively. Adult race 
categories Black, Other, and Hispanic had lower survival rates than Whites, although 
this was not statistically significant (p-value: 0.21). The 5-, 15-, and 30-year survival 
rates are: for adults overall 39%, 36%, and 33%, respectively; for White adults 42%, 
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40%, and 35%; for Black adults 35%, 31%, and 31%, respectively; for Hispanic adults 
30%, 26%, and 26% 18-year survival rate; and for Other adults 35%, 30%, and 30%, 
respectively. 
Univariate and Multivariate Analysis ! Cox proportional hazard regression was performed for both the univariate and 
multivariate analyses. In the univariate analysis (data not shown), adjusted for only age 
at diagnosis and year of diagnosis, Black, Hispanic, and Other race served as 
significant predictors for mortality. After inclusion of all variables in the multivariate 
model, for the entire study period, race is no longer a predictor for mortality (Table 2). 
Black race does trend towards significance with a hazard ratio (HR) of 1.14, and a p-
value of 0.06. Age at diagnosis, histologic type, SEER stage, and prognostic site all 
serve as predictors for mortality when adjusted for all other variables in the model. Year 
of diagnosis and treatment method served as protective factors in the model. When 
stratified by year of diagnosis (Table 3), black race does become a significant predictor 
of mortality (HR: 1.18, 95% CI: 1.01-1.38) in the model for diagnosis from 1990 to 2013. 
Stratifying the model by age of diagnosis (Table 4), Other race becomes predictive in 
children (HR: 1.31, 95% CI: 1.03-1.66). When stratified by race (Table 5), Black adults 
have a higher HR of 2.86 (95% CI: 2.16-3.79) than adults of the other races. Blacks also 
have higher HR’s in regional, distant, and unknown metastasis. Male sex is protective in 
Hispanics (HR: 0.71, 95% CI: 0.55-0.91) in the stratified model. The race category 
“Others” has higher HR’s in all of the histologic subtypes, except for pleomorphic, where 
Whites have the highest HR. 
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Discussion !
This study of 4,268 patients diagnosed with RMS, ages ranging from birth to 98 
years, revealed that race may play an important role in RMS incidence and survival. We 
found that ethnic minorities were more likely than Whites to have mixed-type, spindle 
cell, or alveolar histologies, regional or distant metastasis, unfavorable prognostic tumor 
site, and no treatment. Ethnic minorities were also less likely than Whites to receive 
multimodal treatment of radiation and surgery. The disparity in treatment methods in our 
study could be due to underrepresentation of these populations in RMS clinical trials, 
and therefore hesitance from physicians to administer these therapies in ethnic 
minorities [8,9,10]. Current literature is inconclusive with some reporting statistically 
significant differences in these characteristics by race [7,11,17], and others reporting no 
differences by race [5].  
Blacks were found to have higher RMS incidence rates over the study period 
than Whites. APC in Blacks trended towards an increase, but was not statistically 
significant. Overall RMS APC and APC in Whites did have a statistically significant trend 
downwards, meaning that RMS incidence overall and for Whites is declining. Previous 
studies have found that while males and Black children have higher incidence rates of 
RMS [7,12], there were no differences in survival by gender or race, for both children 
and adults [3,5,11,17]. Although adjusted overall survival was not predicted by race in 
our study, stratification by age group did uncover significant racial survival
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disparities, particularly among children diagnosed with RMS. One study did report that 
Hispanic children seemed to have lower 5-year survival rates than white children for 
certain histologic subtypes [7], though these results were based on a relatively small 
number of children in each category, so caution must be taken in interpreting these 
results.  
 In our study Blacks were found to have a 14% increase in risk for mortality that 
trended towards significance (p-value: 0.06) in the full adjusted model. When the 
analysis was stratified by diagnostic era, the risk for mortality increased to 18% (p-
value: 0.04) in the 1990-2013 diagnostic period. This difference could be the result of an 
increase in sample size, due to the expansion of the SEER registries over the second 
diagnostic period [19].  
Some possible explanations for our findings could be differences in racial/ethnic 
immunization schedule compliance, or differences in genetic predisposition. It has been 
found that children diagnosed with RMS are five-times more likely to have incomplete 
immunization schedules when compared to controls [2]; however, this study did not 
analyze race as a predictor for immunization schedule compliance. Non-white race has 
been found to be a significant predictor of non-compliance to immunization schedules in 
other studies [20]. This could also aid in explaining why a greater proportion of ethnic 
minority children were diagnosed with RMS than white children our study.  
Studies have estimated that ~5% of RMS cases are associated with genetic 
predisposition to several different conditions, such as TP53 mutations (Li-Fraumeni 
syndrome), Costello syndrome, neurofibromatosis, and Beckwith-Wiedeman syndrome 
[1,6,7]. One study in endometrial cancer has found that the incidence in p53 
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overexpression, as a result of TP53 mutations, was higher in Black cases than White 
cases in both early and advanced disease, and that survival was worse in Blacks than 
Whites with similar disease stage and p53 expression [22]. These results may help to 
explain racial disparities in cancers associated with TP53 mutations. TP53 mutations 
have been analyzed in childhood cases of RMS [22], and results have shown that 
patients that carry the TP53 mutation are predisposed to developing RMS at a younger 
age. In this study, a greater percentage of ethnic minority cases were children, 
compared to White cases, with Hispanics containing the highest percentage of children 
(68%). The association between RMS, TP53 mutations, and race has not yet been 
described, but future studies on the topic may aid in explaining why ethnic minorities 
have several significant differences in clinical presentation of RMS than Whites [17].  
A primary strength of using the SEER dataset is that it provides a large sample 
size of RMS cases, over a large period of time, which creates adequate statistical power 
for analysis of this rare malignancy. Data gathered from SEER also provide important 
information on clinical characteristics and treatment methods. Another strength of this 
study is the inclusion of Hispanics and other minority races.  
This study is not without limitations. Survival estimates and incidence rates for 
Whites and Blacks from the SEER 9 database may contain Hispanic data for cases 
diagnosed prior to the SEER 13 expansion in 1992. Analyses on the effect of treatment 
are also limited by the fact that SEER does not collect information on chemotherapy, 
which is a mainstay of RMS management [3,4,8-10,19]; therefore we were unable to 
account for the treatment effect of chemotherapy in the current study. Information on 
diagnoses reported to SEER is rendered by a multitude of oncologists and pathologists 
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with variable equipment and expertise, and there is no central pathological review of this 
information. However, in 1995 the International Classification of RMS (ICR) was 
established, improving the reproducibility of RMS classification, as well as outcome 
prediction [7]. Follow-up for cases in the SEER database is passive, and incomplete 
data is often a problem [5]; this analysis excluded 12 patients (0.3%) due to incomplete 
follow-up data, but it is unlikely this affected the results. Our analysis spans a 40-year 
time period, and within this time period great progress has been made in areas of 
diagnosis and treatment of RMS. It is possible that some RMS NOS and pleomorphic 
cases diagnosed prior to the establishment of the IRC were misdiagnosed, and are 
actually not RMS [3]. The spindle cell variant of RMS was not described until efforts in 
1992 [23] and 1993 [24] made the distinction of this subtype from the more common 
embryonal RMS. Therefore, it is possible that diagnoses of embryonal RMS made prior 
to these two studies may actually be cases of spindle cell RMS [15]. Spindle cell RMS is 
exceedingly rare and most cases of this subtype occur in the favorable prognostic site 
of the paratesticular region [15,23,24], so any affect on the results of this study is likely 
to be small to negligible.
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Conclusion 
Racial disparities in RMS are not yet completely understood, but it is 
thought to be a result of both environmental and socioeconomic factors [11,14]. 
Our study highlights the racial disparities in RMS presentation, incidence, and 
survival in ethnic minorities. Ethnic minorities are at an increased risk for 
developing RMS, and children of ethnic minorities have lower survival rates than 
White children within this study. While RMS incidence is significantly declining 
overall, and in Whites, it is trending upwards for ethnic minorities. Differences in 
incidence rates and clinical characteristics in ethnic minority populations in this 
study may point towards a genetic component in RMS. Future studies should aim 
at describing immunization compliance in ethnic minority children with RMS, 
compared to White children with RMS, as well as describing the link between 
TP53 mutations and RMS by race.!
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Table 1. Characteristics of RMS Patients During Period of 1973-2013 Stratified by Race 
Total 
N=4,268 
N (%) 
NHW 
N=2,601 
N (%) 
NHB 
N=626 
N (%) 
Hispanic 
N=664 
N (%) 
Other* 
N=377 
N (%) 
P-value 
Age at diagnosis 
  Child (0-19 years) 
  Adult (>19 years) 
Median ± SD 
Sex 
  Female 
  Male 
Diagnostic period† 
  1973-1989 
  1990-2013 
Geographic region 
  Northeast 
  Midwest 
  South 
  West 
Histologic type 
  Pleomorphic 
  Mixed-Type 
  Embryonic 
  Spindle Cell 
  Alveolar 
  RMS (NOS) 
Tumor behavior 
  Localized 
  Regional metastasis 
  Distant metastasis 
  Un-staged 
Anatomical site 
  Head and neck‡ 
  Trunk 
  Genitourinary⊺ 
  Orbital 
  Extremity 
  Kidney 
  Prostate 
  Bladder 
  Biliary tract 
  Other/Unknown 
Prognostic site 
  Favorable 
  Unfavorable 
  Unknown 
Treatment 
  No treatment 
  Radiation only 
  Surgery only 
  Radiation & Surgery 
  Either or both    
  treatments unknown 
Vital status 
  Alive 
  Dead 
 
2427 (56.9) 
1841 (43.1) 
 
1395 (53.6) 
1206 (46.4) 
 
357 (57.0) 
269 (43.0) 
 
452 (68.0) 
212 (32.0) 
 
223 (59.2) 
154 (40.8) 
<.0001 
16 ± 26.5 17 ± 28.2 16 ± 23.9 12 ± 21.0 16 ± 24.2  
 
1858 (43.5) 
2410 (56.5) 
 
1110 (42.7) 
1491 (57.3) 
 
288 (46.0) 
338 (54.0) 
 
302 (45.5) 
362 (54.5) 
 
158 (41.9) 
219 (58.1) 
0.29 
 
897 (21.0) 
3371 (79.0) 
 
719 (27.6) 
1882 (72.4) 
 
87 (13.9) 
539 (86.1) 
 
0 (0.0) 
664 (100) 
 
91 (24.1) 
286 (75.9) 
<.0001 
 
659 (15.4) 
675 (15.8) 
686 (16.1) 
2249 (52.7) 
 
479 (18.4) 
548 (21.1) 
394 (15.2) 
1180 (45.4) 
 
79 (12.6) 
104 (16.6) 
233 (37.2) 
210 (33.6) 
 
65 (9.8) 
10 (1.5) 
40 (6.0) 
549 (82.7) 
 
36 (9.5) 
13 (3.5) 
18 (4.8) 
310 (82.3) 
<.0001 
 
395 (9.3) 
72 (1.7) 
1698 (39.8) 
85 (2.0) 
974 (22.8) 
1044 (24.5) 
 
271 (10.4) 
40 (1.5) 
1036 (39.8) 
41 (1.6) 
523 (20.1) 
690 (26.5) 
 
48 (7.7) 
14 (2.2) 
259 (41.4) 
16 (2.6) 
158 (25.2) 
131 (20.9) 
 
41 (6.2) 
15 (2.3) 
261 (39.3) 
23 (3.5) 
198 (29.8) 
126 (19.0) 
 
35 (9.3) 
3 (0.80) 
142 (37.7) 
5 (1.3) 
95 (25.2) 
97(25.7) 
<.0001 
 
1264 (29.6) 
1271 (29.8) 
1234 (28.9) 
499 (11.7) 
 
788 (30.3) 
750 (28.8) 
695 (26.7) 
368 (14.2) 
 
195 (31.2) 
183 (29.2) 
201 (32.1) 
47 (7.5) 
 
166 (25.0) 
217 (32.7) 
230 (34.6) 
51 (7.7) 
 
115 (30.5) 
121 (32.1) 
108 (28.7) 
33 (8.8) 
<.0001 
 
1073 (25.1) 
1247 (29.2) 
662 (15.5) 
199 (4.7) 
789 (18.5) 
16 (0.4) 
94 (2.2) 
112 (2.6) 
28 (0.7) 
48 (1.1) 
 
641 (24.6) 
767 (29.5) 
368 (14.2) 
127 (4.9) 
501 (19.3) 
13 (0.5) 
63 (2.4) 
69 (2.7) 
15 (0.6) 
37 (1.4) 
 
141 (22.5) 
173 (27.6) 
145 (23.2) 
26 (4.2) 
110 (17.6) 
1 (0.2) 
7 (1.1) 
16 (2.6) 
2 (0.3) 
5 (0.8) 
 
196 (29.5) 
187 (28.2) 
101 (15.2) 
24 (3.6) 
110 (16.6) 
1 (0.2) 
15 (2.3) 
18 (2.7) 
9 (1.4) 
3 (0.5) 
 
95 (25.2) 
120 (31.8) 
48 (12.7) 
22 (5.8) 
68 (18.0) 
1 (0.3) 
9 (2.4) 
9 (2.4) 
2 (0.5) 
3 (0.8) 
0.0001 
 
1508 (35.3) 
2712 (63.5) 
48 (1.1) 
 
891 (34.3) 
1673 (64.3) 
37 (1.4) 
 
250 (39.9) 
371 (59.3) 
5 (0.8) 
 
236 (35.5) 
425 (64.0) 
3 (0.5) 
 
131 (34.8) 
243 (64.5) 
3 (0.80) 
0.05 
 
637 (14.9) 
973 (22.8) 
1215 (28.5) 
1300 (30.5) 
143 (3.4) 
 
 
2519 (59.0) 
1749 (41.0) 
 
370 (14.2) 
553 (21.3) 
766 (29.5) 
817 (31.4) 
95 (3.7) 
 
 
1547 (59.5) 
1054 (40.5) 
 
92 (14.7) 
153 (24.4) 
182 (29.1) 
175 (28.0) 
24 (3.8) 
 
 
359 (57.4) 
267 (42.6) 
 
113 (17.0) 
180 (27.1) 
172 (25.9) 
184 (27.7) 
15 (2.3) 
 
 
407 (61.3) 
257 (38.7) 
 
62 (16.5) 
87 (23.1) 
95 (25.2) 
124 (32.9) 
9 (2.4) 
 
 
206 (54.5) 
172 (45.5) 
0.01 
 
 
 
 
 
0.15 
 
      
Abbreviations: SD, standard deviation; HR, hazard ratio; RMS, rhabdomyosarcoma; NOS, not otherwise specified; NHW, 
non-hispanic white; NHB, non-hispanic black; SEER, Surveillance, Epidemiology, and End Results  
*Includes American Indian/Alaskan Native, Asian/Pacific Islander, unspecified and unknown. †The SEER program has expanded since its establishment to cover 9.5% (SEER 9), 13.8% (SEER 13) and 30% (SEER 
18) of the total United States population; therefore, more patients were registered in 1990-2013 period. The latter time 
period also represents a longer time in years. ‡Head and neck, excluding orbital tumors ⊺Genitourinary, excluding kidney, prostate, and bladder tumors 
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Table 2: Multivariate Cox Proportional Hazard Analysis of RMS During Period of 1973-2013 
Period of 1973-2013 
N = 4,268 
n HR (95% CI) P 
Age at diagnosis 
Children 2427 Ref. 
Adults 1841 2.19 (1.97-2.44) <.0001 
Sex 
Female 1858 Ref. 
Male 2410 0.97 (0.88-1.07) 0.57 
Race/ethnicity 
NHW 2601 Ref. 
NHB 626 1.14 (0.99-1.31) 0.06 
Hispanic 664 1.05 (0.91-1.22) 0.52 
Other 377 1.13 (0.96-1.34) 0.15 
Diagnostic period 
1973-1989 897 Ref. 
1990-2013 3371 0.63 (0.56-0.71) <.0001 
Geographic region 
Northeast 659 Ref. 
Midwest 675 1.35 (1.13-1.61) 0.0009 
South 685 1.14 (0.95-1.37) 0.10 
West 2249 1.22 (1.04-1.41) 0.01 
Histologic type 
Embryonic 1698 Ref. 
Pleomorphic 395 1.59 (1.32-1.92) <.0001 
Mixed-type 72 1.80 (1.26-2.57) 0.001 
Spindle cell 85 0.94 (0.59-1.52) 0.81 
Alveolar 974 1.37 (1.21-1.57) <.0001 
RMS (NOS) 1044 1.51 (1.33-1.73) <.0001 
Tumor behavior 
Localized 1264 Ref. 
Regional  1271 1.96 (1.68-2.28) <.0001 
Distant  1234 4.56 (3.92-5.30) <.0001 
Un-staged 499 2.31 (1.91-2.79) <.0001 
Prognostic site 
Favorable site 1508 Ref. 
Unfavorable site 2712 1.38 (1.23-1.55) <.0001 
Unknown 48 2.19 (1.48-3.23) <.0001 
Treatment 
No treatment 637 Ref. 
Radiation only 973 0.64 (0.56-0.74) <.0001 
Surgery only 1215 0.57 (0.49-0.67) <.0001 
Radiation & surgery 
Either or both 
treatments unknown 
1300 
143 
0.48 (0.41-0.55) 
0.71 (0.55-0.92) 
<.0001 
0.001 
Abbreviations: CI, confidence interval; HR, hazard ratio; N, Total number; n, cell number; P, P-value; RMS, 
rhabdomyosarcoma; NOS, not otherwise specified; NHW, non-hispanic white; NHB, non-hispanic black 
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Table 3: Multivariate Cox Proportional Hazard Analysis of RMS Stratified Analysis by 
Diagnostic Period 
  Period of 1973-1989      
N = 897 
Period of 1990-2013       
N = 3,371 
n HR (95% CI) P n HR (95% CI) P 
Age at diagnosis       
Children 480 Ref.  1947 Ref.  
Adults 417 2.56 (2.06-3.18) <.0001 1424 2.11 (1.85-2.39) <.0001 
Sex       
Female 372 Ref.  1486 Ref.  
Male 525 1.11 (0.92-1.34) 0.26 1885 0.93 (0.83-1.04) 0.18 
Race/ethnicity       
NHW 719 Ref.  1882 Ref.  
NHB 87 1.17 (0.86-1.61) 0.32 539 1.18 (1.01-1.38) 0.04 
Hispanic 0 NA ---- 664 1.07 (0.91-1.24) 0.42 
Other 91 1.09 (0.80-1.50) 0.58 286 1.15 (0.95-1.41) 0.16 
Diagnostic period      
1973-1989 ----  ---- ---- ---- 
1990-2013  ---- ----  ---- ---- 
Geographic region       
Northeast 153 Ref.  506 Ref.  
Midwest 318 1.36 (0.98-1.90) 0.07 357 1.26 (1.00-1.59) 0.05 
South 53 0.94 (0.56-1.56) 0.80 632 1.17 (0.96-1.44) 0.13 
West 373 1.24 (0.89-1.73) 0.10 1876 1.20 (1.00-1.43) 0.05 
Histologic type       
Embryonic 391 Ref.  1307 Ref.  
Pleomorphic 60 0.96 (0.63-1.46) 0.83 335 1.97 (1.58-2.45) <.0001 
Mixed-type 10 1.79 (0.79-4.10) 0.17 62 1.83 (1.23-2.72) 0.003 
Spindle cell 0 N/A  85 1.00 (0.62-1.61) 1 
Alveolar 115 1.00 (0.75-1.34) 0.99 859 1.56 (1.34-1.82) <.0001 
RMS (NOS) 321 1.30 (1.03-1.64) 0.03 723 1.63 (1.38-1.93) <.0001 
Tumor behavior       
Localized 327 Ref.  937 Ref.  
Regional  194 1.75 (1.32-2.33) 0.0001 1077 1.98 (1.65-2.39) <.0001 
Distant  213 4.33 (3.31-5.68) <.0001 1021 4.65 (3.86-5.59) <.0001 
Un-staged 163 2.13 (1.57-2.90) <.0001 336 2.30 (1.80-2.95) <.0001 
Prognostic site       
Favorable site 283 Ref.  1225 Ref.  
Unfavorable site 593 1.61 (1.28-2.03) <.0001 2119 1.29 (1.13-1.48) 0.0003 
Unknown 21 2.46 (1.33-4.53) 0.004 27 2.54 (1.51-4.30) 0.0005 
Treatment       
No treatment 116 Ref.  521 Ref.  
Radiation only 160 0.94 (0.69-1.23) 0.70 813 0.57 (0.49-0.67) <.0001 
Surgery only 289 0.56 (0.41-0.78) 0.0004 926 0.59 (0.50-0.71) <.0001 
Radiation & surgery 
Either or both 
treatments unknown 
270 
62 
0.59 (0.43-0.80) 
1.05 (0.66-1.66) 
0.0007 
0.84 
1030 
81 
0.44 (0.37-0.52) 
0.56 (0.39-0.80) 
<.0001 
0.001 
Abbreviations: CI, confidence interval; HR, hazard ratio; N, Total number; n, cell number; P, P-value; RMS, 
rhabdomyosarcoma; NOS, not otherwise specified; NHW, non-hispanic white; NHB, non-hispanic black !
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Table 4. Multivariate Cox Proportional Hazards Analysis of RMS During Period of 1973-
2013, Stratified by Age 
  Child                               
N = 2,427 
Adult                                
N = 1,841 
n HR (95% CI) P n HR (95% CI) P 
Sex       
Female 998 Ref.  860 Ref.  
Male 1429 1.06 (0.92-1.22) 0.42 981 0.93 (0.81-1.06) 0.27 
Race/ethnicity       
NHW 1395 Ref.  1206 Ref.  
NHB 357 1.05 (0.86-1.29) 0.63 269 1.20 (0.99-1.45) 0.07 
Hispanic 452 1.05 (0.86-1.29) 0.65 212 1.07 (0.86-1.33) 0.55 
Other 223 1.31 (1.03-1.66) 0.03 154 0.98 (0.77-1.24) 0.85 
Diagnostic period       
1973-1989 480 Ref.  417 Ref.  
1990-2013 1947 0.62 (0.52-0.74) <.0001 1424 0.63 (0.54-0.75) <.0001 
Geographic region       
Northeast 347 Ref.  312 Ref.  
Midwest 382 1.29 (0.98-1.69) 0.07 293 1.40 (1.10-1.77) 0.006 
South 396 1.22 (0.92-1.61) 0.17 289 1.10 (0.86-1.41) 0.46 
West 1302 1.27 (1.00-1.60) 0.05 947 1.17 (0.96-1.43) 0.11 
Histologic type       
Embryonic 1348 Ref.  350 Ref.  
Pleomorphic 18 2.14 (1.10-4.19) 0.03 377 1.34 (1.07-1.67) 0.01 
Mixed-type 36 1.73 (1.03-2.92) 0.04 36 1.63 (1.00-2.67) 0.05 
Spindle cell 45 0.98 (0.48-1.99) 0.95 40 0.83 (0.44-1.58) 0.57 
Alveolar 682 1.67 (1.42-1.99) <.0001 293 0.99 (0.79-1.23) 0.91 
RMS (NOS) 299 1.58 (1.28-1.95) <.0001 745 1.27 (1.05-1.53) 0.01 
Tumor behavior       
Localized 728 Ref.  536 Ref.  
Regional metastasis 773 2.06 (1.63-2.62) <.0001 498 1.86 (1.51-2.28) <.0001 
Distant metastasis 667 5.07 (4.02-6.38) <.0001 567 3.95 (3.22-4.84) <.0001 
Un-staged 259 2.66 (1.99-3.57) <.0001 240 2.00 (1.55-2.58) <.0001 
Prognostic site       
Favorable site 985 Ref.  523 Ref.  
Unfavorable site 1428 1.53 (1.30-1.81) <.0001 1284 1.26 (1.07-1.49) 0.006 
Unknown 14 3.00 (1.46-6.16) 0.003 34 1.96 (1.22-3.16) 0.006 
Treatment       
No treatment 262 Ref.  375 Ref.  
Radiation only 708 0.69 (0.56-0.84) 0.0003 265 0.63 (0.51-0.77) <.0001 
Surgery only 564 0.62 (0.48-0.79) 0.0001 651 0.52 (0.43-0.64) <.0001 
Radiation & surgery 
Either or both 
treatments unknown 
820 
73 
0.53 (0.43-0.66) 
0.95 (0.65-1.38) 
<.0001 
0.78 
480 
70 
0.44 (0.36-0.54) 
0.60 (0.43-0.85) 
<.0001 
0.004 
Abbreviations: CI, confidence interval; HR, hazard ratio; N, Total number; n, cell number; P, P-value; RMS, 
rhabdomyosarcoma; NOS, not otherwise specified; NHW, non-hispanic white; NHB, non-hispanic black!
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Table 5. Multivariate Cox Proportional Hazards Analysis of RMS During Period of 1973-2013, Stratified by Race/Ethnicity 
  NHW  
N = 2,601 
 NHB 
N = 626 
 Hispanic 
N = 664 
 Other 
N = 377 
 n HR (95% CI) P n HR (95% CI) P n HR (95% CI) P n HR (95% CI) P 
Age             
Children 1395 Ref.  357 Ref.  452 Ref.  223 Ref.  
Adults 1206 2.26 (1.96-2.61) <.0001 269 2.86 (2.16-3.79) <.0001 212 2.25 (1.71-2.97) <.0001 154 1.48 (1.04-2.12) 0.03 
Sex             
Female 1110 Ref.  288 Ref.  302 Ref. 158 Ref. 
Male 1491 1.05 (0.93-1.19) 0.43 338 1.09 (0.85-1.41) 0.49 362 0.71 (0.55-0.91) 0.008 219 0.86 (0.62-1.18) 0.34 
Diagnostic Period             
1973-1989 719 Ref.  87 Ref.  0 Ref.  91 Ref.  
1990-2013 1882 0.63 (0.54-0.72) <.0001 539 0.57 (0.40-0.80) 0.001 664 NE ---- 286 0.67 (0.46-0.98) 0.04 
Geographic region             
Northeast 479 Ref.  79 Ref.  65 Ref.  36 Ref.  
Midwest 548 1.42 (1.16-1.74) 0.0008 104 1.24 (0.75-2.05) 0.40 10 1.43 (0.53-3.89) 0.48 13 2.00 (0.68-5.89) 0.21 
South 394 1.18 (0.94-1.49) 0.15 233 1.24 (0.80-1.90) 0.33 40 0.68 (0.34-1.39) 0.29 18 1.07 (0.37-3.11) 0.90 
West 1180 1.26 (1.05-1.52) 0.01 210 1.21 (0.78-1.88) 0.41 549 0.96 (0.62-1.49) 0.86 310 1.49 (0.74-3.00) 0.27 
Histologic type             
Embryonic 1036 Ref.  259 Ref.  261 Ref.  142 Ref.  
Pleomorphic 271 1.45 (1.14-1.84) 0.003 48 1.76 (1.03-3.02) 0.04 41 1.87 (1.08-3.22) 0.02 35 2.83 (1.51-5.30) 0.001 
Mixed-type 40 2.07 (1.28-3.34) 0.003 14 1.53 (0.70-3.36) 0.29 15 1.46 (0.65-3.29) 0.36 3 3.37 (0.45-25.25) 0.24 
Spindle cell 41 0.69 (0.31-1.56) 0.37 16 0.91 (0.33-2.52) 0.85 23 1.20 (0.54-2.65) 0.65 5 1.29 (0.16-10.15) 0.81 
Alveolar 523 1.33 (1.12-1.57) 0.001 158 1.56 (1.11-2.19) 0.01 198 1.20 (0.85-1.67) 0.30 95 2.07 (1.33-3.23) 0.001 
RMS (NOS) 690 1.44 (1.21-1.71) <.0001 131 1.44 (1.02-2.04) 0.04 126 1.78 (1.24-2.56) 0.002 97 2.19 (1.38-3.48) 0.002 
Tumor behavior             
Localized 788 Ref.  195 Ref.  166 Ref.  115 Ref.  
Regional metastasis 750 1.91 (1.57-2.32) <.0001 183 2.71 (1.80-4.07) <.0001 217 1.97 (1.28-3.01) 0.002 121 1.69 (1.05-2.72) 0.03 
Distant metastasis 695 4.58 (3.77-5.55) <.0001 201 5.69 (3.81-8.48) <.0001 230 4.62 (3.02-7.06) <.0001 108 3.68 (2.27-5.97) <.0001 
Un-staged 368 2.14 (1.70-2.70) <.0001 47 4.05 (2.33-7.03) <.0001 51 2.25 (1.26-4.02) 0.006 33 3.02 (1.54-5.92) 0.001 
Prognostic site             
Favorable site 891 Ref.  250 Ref.  236 Ref.  131 Ref.  
Unfavorable site 1673 1.48 (1.27-1.72) <.0001 371 1.37 (1.02-1.84) 0.04 425 1.31 (0.97-1.78) 0.08 243 1.13 (0.77-1.65) 0.53 
Unknown 37 2.55 (1.62-3.99) <.0001 5 0.51 (0.13-2.01) 0.34 3 8.89(1.95-40.57) 0.005 3 1.02 (0.21-4.95) 0.99 
Treatment             
No treatment 370 Ref.  92 Ref.  113 Ref.  62 Ref.  
Radiation only 553 0.65 (0.53-0.78) <.0001 153 0.67 (0.47-0.95) 0.03 180 0.59 (0.41-0.85) 0.005 87 0.54 (0.34-0.85) 0.008 
Surgery only 766 0.52 (0.42-0.63) <.0001 182 0.82 (0.55-1.22) 0.32 172 0.68 (0.45-1.04) 0.07 95 0.39 (0.24-0.65) 0.0002 
Radiation & surgery 
Either or both 
treatments unknown 
817 
95 
0.46 (0.38-0.56) 
0.83 (0.60-1.14) 
<.0001 
0.24 
175 
24 
0.53 (0.36-0.79) 
0.50 (0.26-0.99) 
0.002 
0.05 
184 
15 
0.57 (0.39-0.84) 
0.70 (0.32-1.51) 
0.004 
0.36 
124 
9 
0.29 (0.18-0.47) 
0.32 (0.11-0.94) 
<.0001 
0.04 
 
Abbreviations: CI, confidence interval; HR, hazard ratio; N, Total number; n, cell number; P, P-value; RMS, rhabdomyosarcoma; NOS, not otherwise specified; NHW, non-hispanic 
white; NHB, non-hispanic black; NE, not estimable!
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Figure 1. RMS Incidence Rates from 1973-2013* 
*Overall, White, and Black rates from SEER 9 incidence data; Hispanic rates from SEER 13 data.!⊺Race/Ethnicity groups are represented by the following symbols: Overall – blue diamonds and a solid line; Whites – red 
squares and a dashed line; Blacks – green triangles and a dotted line; Hispanics – purple crosses and dotted/dashed line. ⋄Data are shown as: Annual Percentage Change (95% Confidence Interval). †Rates are per 100,000 and age-adjusted to the 2000 US Std Population standard. ‡Percentage changes were calculated using 1 year for each end point; Annual Percentage Changes were calculated 
using weighted least squares method.!
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!
Figure 2. Adjusted RMS Survival, by Race* 
*Race/Ethnicity groups are represented by the following symbols: Overall – blue line; Whites – red line; Blacks – green 
line; Hispanics – purple line; Others – orange line. !
 
 
!
Figure 3. RMS Survival in Children and Adults, by Race* 
*Race/Ethnicity groups are represented by the following symbols: Overall Children – solid blue line; Overall Adults – 
dashed blue line; White Children – solid red line; White Adults – dashed red line; Black Children – solid green line; Black 
Adults – dashed green line; Hispanic Children – solid purple line; Hispanic Adults – dashed purple line; Other Children – 
solid orange line; Other Adults – dashed orange line.!
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